- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04136652
Vaginal CO2 Laser for Stress Incontinence
Vaginal CO2 Laser for Stress Incontinence: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patient will be included from our hospital (a Danish academic hospital) among women referred with incontinence. Eligible patients will be randomized to either laser treatment or "sham" laser treatment.
The study will take place in the department of Gynecology and Obstetrics of Hvidovre University Hospital, Copenhagen Denmark in the period of October 2019 to October 2020. Inclusion criteria for the study cohort and controls will be patients, referred from specialist gynecologists or GPs with SUI, that speak and understand Danish, are found without clinical relevant urogenital prolapse (grad 2 at maximum in al compartments), older than 18 years of age, with BMI under 35 and present with mild to moderate SUI evaluated after ICIQ-UI-SF (slight (1-5), moderate (6-12), severe (13-18) and very severe (19-21). Exclusion criteria presence of pelvic organ prolapse greater than stage II, previous pelvic surgery for incontinence or prolaps, current infections, keloid formation, vaginal pain, dyspareunia, ICIQ-UI-SF>=19 (very severe) and ongoing pregnancy.
In this study, women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia. A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault. A burst of laser pulses is transmitted through the probe and deflected at 90degree in four directions towards the vaginal wall, then rotated 45 degrees for a second burst of pulses. Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus. Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
Both study- and placebo- treatments will be performed by specialist gynecologists employed in the department. Patients, who meet inclusion criteria and consent to study participation, will be randomized by computer service to conservative treatment, which encompass local estrogens (Vagifem 10ug twice weekly) if relevant (postmenopausal women) and pelvic floor training supervised by specialised physiotherapists in our own institution, whilst the study cohort will receive the same treatment with the addition of transvaginal laser applied thrice with 25- 45 days apart (CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch). The controls will receive placebo treatment, with the use of the inactive laser, but relevant sound effects.
Primary outcome of the study is patient experienced improvement of SUI evaluated by standardized ICIQ-UI-SF questionnaire.
Our secondary outcome is objective improvement as measured by standardized stress test performed by specialist nurse before treatment and 1-2 month after last laser or placebo treatment. The bladder is emptied with a catheter and 300ml of saline is inserted. The patient is then stood up wearing a pad with legs slightly apart and asked to forcefully cough 10 timers, jump 10 times and make 10 squats. The examiner registers whether there is incontinence as either yes or no as well as grams of urin leakage in the pad. Furthermore, side- effects both positive and negative as well as patient satisfaction will be registered by the use of patient questionnaires at 1-2 months post treatment.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Hrefna B Sigurdardóttir, MD
- Phone Number: 004528481538
- Email: hrefna.boel.sigurdardottir@regionh.dk
Study Contact Backup
- Name: Jeppe B Schroll, MD, PhD
- Email: jeppe.bennekou.schroll.02@regionh.dk
Study Locations
-
-
-
Hvidovre, Denmark, 2650
- Hvidovre University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria
- referred from specialist gynecologists or GPs with SUI
- speak and understand Danish
- are found without clinical relevant urogenital prolapse
- older than 18 years of age
- with BMI under 35
- Present with mild to moderate SUI evaluated after ICIQ-UI-SF (slight (1-5), moderate (6-12), severe (13-18) and very severe (19-21))
Exclusion criteria
- presence of pelvic organ prolapse greater than stage II
- previous pelvic surgery for prolapse or incontinence,
- current infections,
- keloid formation
- vaginal pain
- dyspareunia,
- ICIQ-UI-SF>=19 (very severe)
- ongoing pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sham
The women are randomized, by a computer program, to a sham laser-treatment with the laser not active.
|
women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia.
A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault.
A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses.
Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus.
Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
|
Active Comparator: Laser
The women are randomized, by a computer program, to a vaginal CO2 laser-treatment with 30 w.
|
women will receive a series of three treatments using a fractional (pulsed) CO2 laser system (SmartXide2 MonaLisa Touch, DEKA M.E.L.A Srl, Florence, Italy), each performed in an outpatient setting without analgesia.
A tubular laser-probe is inserted in the vaginal canal until reaching the vaginal vault.
A burst of laser pulses is transmitted through the probe and deflected at 90degrees in four directions towards the vaginal wall, then rotated 45degree for a second burst of pulses.
Guided by markings on the probe, it is withdrawn 4mm and the procedure is repeated until reaching the introitus.
Treatment parameters include power 30W, dwell time 1000us, 1000um spacing, using normal scan mode, with Smartstack setting for 1 at first application and 3 for the next two applications.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ICIQ-UI SF
Time Frame: Through study completion, an average of 6-8 months
|
The ICIQ-UI Short Form is a questionnaire for evaluating the frequency, severity and impact on quality of life (QoL) of urinary incontinence in men and women in research and clinical practice across the world.
Women will answer this questionnaire before they are booked for the first laser treatment.
After al three treatments, they will have a control visit in an outpatient setting, where they fill out the questionaire again.
|
Through study completion, an average of 6-8 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Standardized stress test
Time Frame: Through study completion, an average of 6-8 months
|
Objective improvement as measured by standardized stress test performed by specialist nurse before treatment and 1-2 month after last laser or placebo treatment.
The bladder is emptied with a catheter and 300ml of saline is inserted.
The patient is then stood up wearing a pad with legs slightly apart and asked to forcefully cough 10 times, jump 10 times and do 10 squats.
The examiner registers whether there is incontinence as either yes or no as well as grams of urin leakage in the pad
|
Through study completion, an average of 6-8 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Jeppe B Schroll, MD, PhD, Hvidovre University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-19013894
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Laser
-
Chinese University of Hong KongCompletedAwake Laser | Microlaryngeal Surgery | Benign Laryngeal Lesion | Transnasal Laser SurgeryHong Kong
-
Huazhong University of Science and TechnologyCompleted
-
Goldman, Butterwick, Fitzpatrick and GroffCompletedExposure LaserUnited States
-
National Taiwan University HospitalBRIDGECON CO,.LTD.RecruitingLaser | PeriorbitalTaiwan
-
Kaohsiung Medical University Chung-Ho Memorial...Completed
-
Kaohsiung Veterans General Hospital.UnknownEndometrium | LaserTaiwan
-
Cairo UniversityUnknownStriae Distensae | Fractional CO2 Laser | Striae; Albicantes | Striae Alba | Nd-YAG Laser | High Frequency Skin Ultrasound | Short Pulsed Nd-YAG | Carbon Dioxide Laser | Neodymium-Doped Yttrium Aluminum Garnet LaserEgypt
-
Cutera Inc.WithdrawnLaser Tattoo RemovalCanada
-
Merve Erkmen AlmazCompleted
-
Alma LasersActive, not recruitingLaser Assisted LiposuctionUnited States
Clinical Trials on CO2 laser- treatment (DEKA SmartXide2 Laser System, MonaLisa Touch
-
National and Kapodistrian University of AthensCompletedOveractive Bladder (OAB)Greece
-
National and Kapodistrian University of AthensIRCCS San RaffaeleUnknown
-
National and Kapodistrian University of AthensUnknownVaginal Dryness | Dyspareunia | Gynecological Cancer | Pelvic RadiotherapyGreece
-
National and Kapodistrian University of AthensUnknownBreast Cancer | Vaginal Atrophy | Dyspareunia | Genitourinary Syndrome of MenopauseGreece
-
University Hospital Inselspital, BerneDeka Medical, Inc.Active, not recruitingLichen Sclerosus Et Atrophicus of the VulvaSwitzerland
-
Faculdade de Medicina do ABCCompleted
-
Hopital Nord Franche-ComteActive, not recruitingGenitourinary Syndrome of MenopauseFrance
-
Royal North Shore HospitalUnknownVulvovaginal Atrophy | Genitourinary Symptoms and Ill-Defined ConditionsAustralia
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloEnrolling by invitationGenitourinary Symptoms | Postmenopausal Symptoms | Postmenopausal Atrophic VaginitisBrazil
-
University of Texas Southwestern Medical CenterWithdrawnLichen Planus PigmentosusUnited States